Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.
Nieto Y, Ramdial J, Valdez B, Thall PF, Bassett R, Barnett M, Srour S, Hosing C, Alousi A, Qazilbash M, Popat U, Gulbis A, Shigle TL, Ahmed S, Guillermo Pacheco M, Champlin R, Shpall EJ, Andersson BS. Nieto Y, et al. Among authors: thall pf. Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-3544. Online ahead of print. Clin Cancer Res. 2025. PMID: 39804167
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P. Berg SA, et al. Among authors: thall pf. Urol Oncol. 2024 Nov 4:S1078-1439(24)00701-4. doi: 10.1016/j.urolonc.2024.10.022. Online ahead of print. Urol Oncol. 2024. PMID: 39500687 Free article. Review.
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Ramdial J, et al. Among authors: thall pf. Bone Marrow Transplant. 2024 Dec;59(12):1754-1762. doi: 10.1038/s41409-024-02394-0. Epub 2024 Sep 28. Bone Marrow Transplant. 2024. PMID: 39341929 Free PMC article.
Signet ring cells and conditional survival after trimodality therapy for esophageal adenocarcinoma.
Mitchell KG, Feldman H, Milton DR, Antonoff MB, Hofstetter WL, Rice DC, Vaporciyan AA, Lin R, Thall PF, Rajaram R; and other members of the MD Anderson Cancer Center Esophageal Adenocarcinoma Study Group. Mitchell KG, et al. Among authors: thall pf. J Surg Oncol. 2024 Sep;130(3):428-434. doi: 10.1002/jso.27774. Epub 2024 Jul 14. J Surg Oncol. 2024. PMID: 39004940
242 results